The approval of Wellbutrin® XL for this indication represents a significant milestone for Biovail and for Canadian healthcare, as it represents the first ...
TORONTO - Biovail Corp. said Friday that Canadian health regulators have approved the use of its Wellbutrin XL antidepressant for the treatment of seasonal ...
Five of Glaxo's best-selling medicines will lose patent protection in 2008: Lamictal for epilepsy, antidepressants Wellbutrin XL and Paxil CR, migraine pill ...
TORONTO - Biovail Corp. said Friday that Canadian health regulators have approved the use of its Wellbutrin XL antidepressant for the treatment of seasonal ...
The approval of Wellbutrin XL in seasonal major depressive illness represents Biovail's third Notice of Compliance in the past six months. ...
The efficacy of Wellbutrin XL for the prevention of seasonal major depressive episodes was established in three, double blind, placebo-controlled trials in ...
all 19 news articles
Wellbutrin XL was developed by Biovail as an extended-release version of the successful antidepressant that goes by the same name (sans the "XL"). ...
Weakness in the US dollar and a substantial reduction in Avandia sales and generic competition to Flonase, Wellbutrin XL, Zofran and Coreg IR weighed on the ...
At the same time, five medicines will lose patent protection this year: Lamictal for epilepsy, the antidepressants Wellbutrin XL and Paxil CR, the migraine ...